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Introduction
　Nonfunctioning pituitary adenomas （NFPA） lack the hormone-related clinical signs and 
symptoms characteristic of most pituitary tumors.  Comprising around 30％ of all pituitary 
adenomas, NFPA do not manifest clinically in easily recognizable pituitary hypersecretory 
syndromes and consequently, the associated tumors are often large when finally detected. 
Headaches and visual-field deficits due to compression of the optic nerve is therefore a 
common presentation for patients with NFPA and most preliminary scan results in these 
patients reveal neuro-ophthalmological or neurological symptoms 1-3）.  Early detection of 
adenomas leads to more effective treatments, thus the challenge for better prognoses in 
NFPA patients is identifying testable peculiarities of this disease.
　Patients with NFPA have normal circulating levels of anterior pituitary hormone. 
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Gonadotropin-producing adenoma is clinically classified among the NFPA, because most 
cases present with normal levels of gonadotropin.  In contrast, cases of functioning pituitary 
adenomas including prolactinoma and growth hormone （GH）-producing adenoma show 
increased circulating levels of prolactin （PRL） and GH, respectively 4）.  It was therefore 
proposed that gonadotropin-producing adenoma cells might have defective hormone-secretion 
mechanisms, although this has yet to be conrmed experimentally5-9）.
　Gonadotropin-producing adenoma cells contain vesicles that transport follicle-stimulating 
hormone （FSH）-β and lutenizing hormone （LH）-β10-11）.  The Rab family of GTPase 
proteins regulates vesicular transport during all stages of intracellular protein trafficking, 
including the multiple and complex pathways of endocrine cells 12）.  Pituitary endocrine cells 
express several Rabs including Rab27b and Rab3a.  Rab27 regulates the delivery of granules 
to the exocytic site and the Rab27b isoform has been localized on pituitary endocrine 
granules 13）.  Izumi’s group reported tissue-specic expression of Rab27b in C57BL / 6J mice, 
including in the brain and pituitary, and that Rab27b was differentially expressed in the 
various pituitary cell types that secrete different hormones10, 14）.  Rab3 proteins also have 
been associated with secretory vesicles, and several studies showed coexpression of Rab27b 
and Rab3a in secretory neuron cells15）.  However, Rab3a-deficient synapses displayed an 
enhanced rundown of synaptic transmission, implicating an inhibitory role for Rab3a in 
vesicle fusion 19）.  It is therefore possible that Rab3 and Rab27 have different functions on 
secretory vesicles 16-19）.  This study investigated the pathological signicance of Rab proteins 
in human pituitary adenomas.  We examined the expression of both Rab27b and Rab3a in 
surgically dissected pituitary adenomas by immunohistochemical （IHC） analysis.
Materials and Methods
Subjects
　The study comprised 74 patients who underwent surgical resection for pituitary adenoma 
by T.  Abe’s cohort at Showa University Hospital from 1999 to 200820）.  The diagnoses 
included two types of NFPA 〔gonadotropin-producing （Gn） adenoma and null-cell 
（Null） adenoma〕 and two types of functioning adenomas （PRL-producing adenoma and 
GH-producing adenoma）, as follows : 16 Gn tumors, 23 Null adenomas, 17 GH-producing 
adenomas, and 18 PRL-producing adenomas （Table 1）21）.  The Showa University Ethics 
Review Board approved the study protocol.
Immunostaining
　Sections of the tumor samples were deparafnized, washed, and then incubated in 0.3％ 
H2O2 for 10 min to block endogenous peroxidase activity.  The sections were then incubated 
in nonspecific blocking reagent （DAKO X0909） for 5 min to block nonspecific staining, 
before the primary antibody incubations in mouse anti-Rab3a monoclonal antibody （BR-
039, Innogenetics, Gent, Belgium） diluted 1 : 100 in Dako Antibody Diluent （DAKO S0809） 
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for 30 min at room temperature.  The sections were nally incubated for 30 min in HRP-
labeled anti-mouse secondary antibody （K4007, Dako, Glostrup, Denmark） and counter-
stained with Tissue-Tek hematoxylin.  No-primary-antibody negative controls were run on 
parallel sections.
Immunouorescence
　Some of each resected tissue was also embedded in OCT compound （Sakura, Torrance, 
CA） and then snap frozen with isopentane cooled in liquid nitrogen.  Frozen sections were 
cut at a thickness of 5μm and fixed in 10％ formaldehyde.  These sections were again 
incubated in 0.3％ H2O2 for 5 min to remove endogenous peroxidase activity and then in 
the Dako nonspecic blocking reagent for 5 min.  Sections were then incubated with goat 
anti-Rab27b polyclonal antibody （sc-22991, Santa Cruz Biotechnology, CA） for 1 h at room 
temperature, followed by FITC-conjugated anti-goat IgG （F0250, Dako） as a secondary 
antibody in a humid chamber at 37℃ for 30 min.  The same sections were then washed 
thoroughly before incubation with mouse anti-Rab3a monoclonal antibody （BR-039, Innoge-
netics） at 37℃ for 1 h, and then a TRIC-conjugated anti-mouse lgG （F0270, Dako） as sec-
ondary antibody for 30 min.  Sections were systematically counterstained with Bisbenzimide 
H33342 （Hoechst 33342）, and then viewed on a Nikon A1 confocal microscope.
　Immunoreactivity grading was based on the German Immunoreactive score22）.  Staining 
intensity in the cytoplasm was rated on a scale from 0 to 3, with 0 being no staining at all, 
1 weak staining, 2 moderate, and 3 strong staining.
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　For statistical purposes, two groups were formed : negative immunoreactivity was Negative 
（scale 0）; weak and moderate and strong immunoreactivity were Positive （scale 1-3）.
Statistical analysis
　Characteristics between pituitary adenomas were compared statistically using the Fisher 
exact test for categorical variables.  Results are expressed as mean ＋ / - SD and statistical 
signicance was set at P＜ 0.01.
Results
　The relationship between Rab27b / Rab3a expression and pituitary adenoma pathology was 
investigated in this study by IHC analysis of NFPA and other pituitary adenoma samples. 
Hematoxylin / eosin （HE）-stained sections showed the papillary type cells that are typical 
of a pituitary adenoma in both Null and Gn adenomas （Fig. 1A, B）.  PRL adenomas dis-
played a diffuse-type cell pattern （Fig. 1C）, while GH adenoma cells were acidophilic （Fig. 
1D）.  We then examined Rab3a expression in these human pituitary adenoma tissues （Fig. 
1E-H）.   A negative control was included in each run （obtained by omitting the primary 
antibody）.  Nonspecicity of Rab3a was not expressed （Fig. 1I-L）.  We examined Rab27b 
expression in these human pituitary adenoma tissues （Fig. 1M-P）.  A negative control was 
included.  Nonspecicity of Rab27b was not expressed （Fig. 1Q-T）.
　The PRL and GH adenomas showed immunostaining of Rab3a （Fig. 1G, H）, while full 
IHC analysis indicated that every section of functional adenoma tissue, including PRL and 
GH adenomas, was graded as positive for Rab3a expression （Table 2）.  In contrast, sections 
from the Null and Gn adenoma tissues were negative for Rab3a immunostaining （Fig. 1E, 
F）, with the quantitation indicating that 43.5％ （10 / 23） of Null adenoma samples and 
25.0％ （4 / 16） of Gn adenoma samples were Rab3a（-） （Table 2）.
　We next assessed the coexpression of Rab27b and Rab3a in adenoma cells by double 
immunouorescence staining.  The Rab3a（-） null samples （Fig. 2F, H） showed low Rab27b 
expression（Fig. 2A, C）, as was the case for the Rab3a（-） Gn adenoma tissue sections 
（data not shown）.  In contrast, the Rab3a（＋） PRL- and GH-producing functional adenoma 
tissues （Fig. 2I, J） also expressed Rab27b （Fig. 2D, F）.  The merged images clearly 
demonstrate coexpression at a cellular level, with both Rab3a and Rab27b visible in the 
cytoplasm of most pituitary adenoma cells （Fig. 2N, O）.  The areas of coexpression in the 
nonfunctional adenoma tissues （Fig. 2K-M） were less in extent than those in the functional 
adenomas （Fig. 2 F, H）.
　All functioning adenomas （PRL- and GH-producing tumors） showed positive staining for 
both Rab27b and Rab3a.  In contrast, Rab27b（＋） cells were largely absent from the NFPA 
tumors, including 69.6％ （16 / 23） of Null adenomas and 37.5％ （6 / 16） of Gn adenoma 
samples （Table 3）.
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Discussion
　Rab-family proteins are essential for all intracellular trafficking pathways.  Rab proteins 
are small G proteins linked to biological membranes via lipid modications.  In neuroendo-
Fig. 1.  Rab3a and Rab27b expression in human pituitary adenomas. 
（A-D） Hematoxylin / eosin （HE）-stained sections of human pituitary adenomas, including null cell 
adenoma （Null） （A）, gonadotropin adenoma （Gn） （B）, prolactin secretion adenoma （PRL） （C）, and 
growth hormone secretion adenoma. （GH） （D）. Rab3a expression was detected in Null （E）, Gn （F）, 
PRL （G）, and GH tissues （H）. Rab3a was not expressed, Null （I）, Gn （J）, PRL （K）, and GH tissues 
（L）. Rab27b expression was detected in Null （M）, Gn （N）, PRL （O）, and GH tissues （P）. Rab27b 
were not expressed, Null （Q）, Gn （R）, PRL （S）, and GH tissues （T）. Magnication : ×400.
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Fig. 2.  Immunouorescent staining of Rab3a and Rab27b.
Null Rab27b（＋）Rab3a（-）（A）, Rab27b（-）Rab3a（＋）（B）, Rab27b（-）Rab3a（-）,（C）, samples expressed 
lower levels of Rab27b than PRL （D） and GH （E）. Rab3a expression was detected in Null Rab27b（-）Rab3a
（＋） （G）, PRL （I）, and GH （J）. The merged images represent double staining of Null （K-M）, PRL （N）, and 
GH （O）. Inset magnications : ×600.
Table 2.  Immunohistochemical expression of Rab3a
Rab3a expression
Characteristics n Negative （％） Positive （％） P value
PRL adenoma 18 0 18 （100）
GH adenoma 17 0 17 （100） NS
Gonadotropin adenoma 16 4 （25） 12 （75） 0.072
Null cell adenoma 23 10 （43.5） 13 （56.5） 0.002
Table 3.  Immunohistochemical expression of Rab27b
Rab27b expression
Characteristics n Negative （％） Positive （％） P value
PRL adenoma 18 0 18 （100）
GH adenoma 17 0 17 （100） NS
Gonadotropin adenoma 16 6 （37.5） 10 （62.5） 0.006
Null cell adenoma 23 16 （69.6） 7 （30.4） ＜ 0.001
189Rab3a and Rab27b Expression Analysis of NFPA
crine cells, Rab proteins are recruited to the membranes of hormone-carrying vesicles and 
granules to help regulate both their trafcking and membrane fusion.  Rab3a and Rab27b 
often cooperate in hormone-secretion pathways of neuroendocrine cells, and both have been 
associated with exocytotic vesicles23, 24）.
　In this study, all functioning pituitary adenoma tissues from our patient cohort （PRL 
and GH） were immunopositive for both Rab27b and Rab3a expression.  In contrast, some 
of the nonfunctioning adenoma tissues （Null and Gn adenoma） expressed neither Rab27b 
nor Rab3a.  Both Rab27b and Rab3a have been implicated as essential regulators of 
neurotransmitter and hormone secretion25-28）, and this study now suggests a potential clinical 
application of this basic knowledge about Rab proteins.  Specically, a Rab27b（-）Rab3a（-） 
pattern of expression might be a prognostic determiner of nonfunctioning adenoma cells, and 
IHC analysis for Rab27b and Rab3a could constitute part of the pathological testing.
　Table 4 summarizes the coexpression of Rab3a and Rab27b in each pituitary adenoma. 
In total, 8 Null samples and 3 Gn adenoma tissues were negative for both Rab27b and 
Rab3a by IHC analysis 〔Rab27b（-）Rab3a（-）〕, suggesting that the vesicle trafcking system 
would be downregulated or defective in those coexpressing tumor cells.  Contrary to our 
expectations, Rab27b（＋）Rab3a（＋） samples were also observed among the NFPA resec-
tions, suggesting the presence of other factors that could suppress hormone secretion such as 
inhibitors of protein synthesis, Rab inhibitors, or defective SNARE proteins.  Gn adenoma 
cells have the capacity for hormone production, and the IHC experiments overall revealed 
various Rab expression patterns for the Gn adenoma sampled in this study, namely Rab27b
（-）Rab3a（-）, Rab27b（＋）Rab3a（-）, Rab27b（-）Rab3a（＋）, and Rab27b（＋）Rab3a（＋） 
（Table 4）.
　The two types of adenoma, Null and Gn are classied as NFPA, because these adenoma 
cells do not secrete hormones.  However, these adenoma types differ in the degree of 
cellular differentiation.  During the earliest stages of anterior pituitary development, the α- 
subunit of undifferentiated cells appears in Rathke’s pouch, and specific factors act on 
Pit1 and Prop1 to induce the respective differentiation pathways to TSH-, PRL-, and 
GH-secreting cells6）.  We proposed therefore that when these transcription factors do not 
function, as in the Null adenomas, proper differentiation is halted and the various hormones 
are not made and not secreted 29）.  In contrast, Gn adenoma can synthesize hormones, but 









Rab27b（-）Rab3a（-） 8 （34.7） 3 （18.7） 0 0
Rab27b（＋）Rab3a（-） 2  （8.6） 1  （6.2） 0 0
Rab27b（-）Rab3a（＋） 8 （34.7） 3 （18.7） 0 0
Rab27b（＋）Rab3a（＋） 5 （21.7） 9 （56.2） 17 （100） 18 （100）
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not secrete them.  We propose therefore that Null adenoma is an undifferentiated pituitary 
tumor tissue, while Gn adenoma tissues have undergone some differentiation30）.  On the 
other hand, functioning pituitary adenomas （e.g., PRL and GH） represent highly differenti-
ated pituitary tissues with proliferative capacity.  Based on this study, we therefore concluded 
that the hormone synthesis system during the pituitary differentiation process was followed 
by development of the secretion mechanisms.
　Null-cell adenoma cells do not synthesize hormone, but many differently sized vesicles 
（50-250 nm in diameter） can be seen inside these cells by electron microscopy.  In addition, 
Gn adenomas cells contain many hormone-containing vesicles of a similar size （about 150 
nm diameter）31）.  It is thought that nonfunctioning adenoma cells contain hormone-carrying 
vesicles, but do not secrete the vesicle contents 32）.  The enrichment of vesicles observed 
in the nonfunctioning adenoma cells might therefore be attributed to defects in exocytosis 
that prevent vesicle fusion and release.  Table 4 indicates that 64％ of nonfunctioning 
adenoma samples （25 / 39 samples） in the present study were IHC-negative for Rab27b 
and / or Rab3a, supporting our initial hypothesis that such low expression might underlie 
the suspected exocytic trafficking defects based on reported functions for these Rabs in 
granule delivery at the cell membrane.  Our results also confirmed that expression levels 
closely parallel the pathology of the NFPA.  Indeed, localization of the Rab-immunopositive 
vesicles near the plasma membrane in some cells implied a problem with membrane fusion, 
but not with vesicle formation or delivery.  All functioning pituitary adenomas studied here 
were IHC-positive for both Rab27b and Rab3a, corroborating reports that hormone secre-
tion from pituitary endocrine cells requires the expression of these Rabs.  In addition, the 
heterogeneous pattern of Rab27b / Rab3a expression in the various NFPA samples indicated 
that double IHC analysis of Rab27b and Rab3a could inform a more precise diagnosis of 
these types of pituitary adenoma.
　The results of the present study showed expression of selected Rab proteins in all func-
tioning hormone-secreting pituitary tumors, but at levels below the experimental detection 
limits in some NFPA.  These ndings suggested that the immunodetection of Rab proteins 
could supplement the pathological diagnosis of NFPA.  In addition, there were both anti-
body-negative and antibody-positive samples analyzed in this group of patients, and it may 
be possible to further classify nonfunctioning adenomas based on hormone exocytosis and 
secretion.  The number of cases analyzed herein was low, and further studies should include 
more Gn adenoma subjects for Rab3a immunostaining examination in particular.  We would 
predict a signicant difference in the number of Rab3a-negative cells between the Gn and 
functional adenomas.  An interesting and unexpected result, given our hypothesis, was the 
presence of some Rab27b（＋）Rab3a（＋） samples among the NFPA patients.  This was an 
apparent contradiction between the expected NFPA pathology and Rab-protein expression. 
Although further studies on these samples are needed, we would suggest that an inhibitor 
of exocytosis is acting in such cells to interrupt the Rab functions in membrane fusion and 
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hormone release.
　In the future, we plan to establish the pathological classication of nonfunctioning tumors 
by analyzing the expression of Rab proteins in many patients with nonfunctioning pituitary 
tumors and develop a method to differentiate nonfunctioning adenoma cells at the molecu-
lar level.
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